First case report of perioperative immunochemotherapy with envafolimab in pulmonary large-cell neuroendocrine carcinoma
Pulmonary large-cell neuroendocrine carcinoma (PLCNEC) is a rare and highly aggressive cancer with no standardized perioperative treatment. This study aimed to explore the efficacy and safety of perioperative immunochemotherapy with envafolimab for resectable PLCNEC. We report a 67-year-old male patient with stage IIIA PLCNEC (cT4N0M0) who received four cycles of neoadjuvant immunochemotherapy (envafolimab + carboplatin + etoposide), followed by radical surgery and adjuvant therapy. After neoadjuvant treatment, the tumor shrank by 48.1% and achieved partial response. The patient underwent successful R0 resection and achieved major pathological response. As of May 2025, the patient remained disease-free for 29 months postoperatively, with no grade greater than or equal to 3 adverse events. Notably, clinical benefit was achieved despite negative programmed death-ligand 1 (PD-L1) expression. Perioperative immunochemotherapy with envafolimab is a promising therapeutic option for patients with resectable PLCNEC, even in those with negative PD-L1 expression.
Authors
- Huidong Long
- Yunen Lin (ORCID: https://orcid.org/0000-0002-6408-013X)
- Jin-Yu Zhou
Institutions
- Guangzhou Medical University Cancer Hospital (CN)
- Guangzhou Chest Hospital (CN)
Publication Details
- Journal
- Anti-Cancer Drugs
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1097/cad.0000000000001851
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00